


 Cite this: *RSC Adv.*, 2020, **10**, 23975

Use of exosomes as vectors to carry advanced therapies

 María Sancho-Albero, ^{ab} Ana Medel-Martínez ^{ac} and Pilar Martín-Duque ^{*bcd}

Exosomes are microvesicles of nanometric size involved in the communication between cells and tissues. Inside their bilipidic membrane they carry nucleic acids such as cargos (DNA, miRNA, etc.). Some of the advantages that make exosomes very attractive therapeutic vehicles are (i) their tropism through different tissues, (ii) the ability to pass biological barriers and (iii) the protection of the encapsulated material from the immune system and degradation. Viruses are some of the most widely employed gene therapy vehicles; however, they are still facing many problems, such as inefficient tropism to damaged areas and their elimination by the immune system. One of the functions attributed to exosomes is the elimination of substances that could be harmful to the cell, including viruses. Recently it has been investigated whether complete viruses or part of them could be encapsulated in exosomes, for a new viral-exosome gene therapy approach. Moreover, nanotechnology is another type of advanced therapy (together with gene and cell therapies) that can be used, among other utilities, to transfer genetic material. Recently the field of encapsulation of nanomaterials in exosomes, with or without gene transfer, is increasing. In this review we will summarize all of those studies.

Received 15th March 2020

Accepted 13th June 2020

DOI: 10.1039/d0ra02414g

rsc.li/rsc-advances

^aDepartment of Chemical Engineering, Aragon Institute of Nanoscience (INA), Aragon Materials Science Institute (ICMA), University of Zaragoza, Campus Río Ebro-Edificio I+D, C/Poeta Mariano Esquillor s/n, 50018 Zaragoza, Spain

^bNetworking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), 28029 Madrid, Spain. E-mail: mpmartind.iacs@aragon.es

^cAragon Health Sciences Institute(IACS)/IIS Aragón, Centro de Investigaciones Biomédicas de Aragón, Avda San Juan Bosco 13, 50009 Zaragoza, Spain

^dAraid Fund., Av. de Ranillas 1-D, Planta 2^a, Oficina B, 50018 Zaragoza, Spain



María Sancho Albero: BSc in Biotechnology and MSc in Nanostructured Materials at the University of Zaragoza. PhD student in the Nanoscience Institute of Aragon (INA) in the NFP group. She works on the combinations of molecular biology and biochemistry with physicochemical, microfluidics and nanotechnological techniques in the field of extracellular vesicles for cancer

treatment and diagnosis. She made two international research stays in the ETH of Zurich and in the Polytechnic University of Milan. She has published articles in high impact journals such as: M. Sancho-Albero, et al., *Nat Catal.*, 2019, **2**(10), 864–872, DOI: 10.1038/s41929-019-0333-4; M. Sancho-Albero, et al., *Nanoscale*, 2019, **11**(40), 18825–18836, DOI: 10.1039/C9NR06183E; M. Sancho-Albero, et al., *J Nanobiotechnol*, 2019, **17**(1), 1–16, DOI: 10.1186/s12951-018-0437-z.



Ana Medel Martínez: BSc in Biology and MSC in Therapeutic Targets and Cell Signaling at the University of Alcalá. PhD student at the Aragonese Institute of Health Sciences (IACS) in the gene and cell therapy group. Member of the DGA's NFP group. She works on the combination of molecular biology, virology and extracellular vesicles fields for both treatment and diagnosis of inflammatory pathologies.

Although she is still in her first years at doctoral school, she has made several national stays with other groups (Biomedical Signal Interpretation and Computational Simulation) and companies (WorldPathol S.L.). She is currently involved in a project related to COVID-19 disease with promising results.



Exosomes: general overview and their role as therapeutic carriers

Exosomes are one subset of extracellular vesicles (EVs) secreted by almost all cells present in the organism.¹ Apart from exosomes, other EVs including apoptotic bodies, ectosomes and microvesicles are also released to the extracellular environment.² Exosomes are the smallest EVs from endocytic nature with a diameter from 30 to 100 nm and they are formed by the maturation of the early endosomes to the late endosomes, followed by the invagination of the endosomal membrane and the formation of the multivesicular bodies (MVBs).³ Afterwards, MVBs are fused with the plasmatic membrane and exosomes are finally released to the extracellular space.⁴ In fact, they could be found in almost all body fluids such as blood, serum, saliva, nasal secretions, urine, breast milk, pericardial fluid, *etc.*⁵

Those “nanospheres” have a density between 1.08 and 1.22 g mL⁻¹ and they are surrounded by a lipid bilayer membrane similar to the plasmatic one, but enriched in certain lipids such as sphingomyelin, phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, ceramide and cholesterol.^{6,7} Apart from lipids, exosome membrane also contains proteins (surface receptors and ligands) that might be different depending of the cell source. Among them, transporter proteins (CD13), heat shock proteins (Hsp70), fusion proteins (flotilin or annexin), proteins related to the biogenesis process and tetraspanins (CD63, CD81 or CD9) are some of the common ones.⁸ Those proteins were mostly found in exosomes, rather than in other EVs, allowing their distinction from other vesicles. In the cytosolic compartment, exosomes carry a wide variety of proteins identified as components of the Endosomal Sorting Complex Required for Transport (ESCRT) machinery, such as ALIX or VPS and RAB proteins. Moreover, metabolic enzymes (ATPase or aldehyde reductase), growth factors and cytokines (such as TNF)

are also found inside exosomes.⁹ Apart from proteins, exosomes also contain different patterns of nucleic acids such as mRNAs and miRNAs (mi-214, miR-29a or miR-126)^{10,11} or even, double strand DNA.¹² Although those biomolecules are contained in all types of exosomes, those vesicles also have a specific cargo that is closely associated with the parental cell, which determines exosome function and targets.^{13,14}

Despite their homogeneity, exosomes mediate a wide range of functions and thus, and it has been demonstrated that those vesicles have different content on composition depending on the parental cell.^{3,15} In fact, Palma *et al.*, showed that tumor and healthy cells release distinct populations of exosomes.¹⁶

On the past, the main role attributed to exosomes was the release of unnecessary or toxic materials for the cell (such as unfolded proteins).¹⁷ On the contrary, today those vesicles are considered as natural signaling vectors and they are thought to play an essential role for the intercellular local and distant communication.¹⁸ In fact, one of the most useful characteristic of exosomes is their ability to cross biological barriers including the blood brain barrier (BBB) or the cytoplasmic membrane.¹⁹ That fact allows us to transport selectively specific therapies to certain cell types or to inaccessible sites such as the central nervous system and in particular to the brain, which remains a major challenge. Apart from their role in cell–cell communication, they participate in the transport of small molecules amongst cells regulating a wide range of functions often immunity related (they have been proposed to be crucial in the development of organs or in some pathologies,²⁰ such as neurodegenerative diseases of the brain²¹ and in cardiovascular diseases²²). Due to their central role in the intercellular communication to recipient cells, exosomes are also essential for the interaction between tumor cells and their environment, and thus they are involved in cancer progression pathways, such as evasion of the immune system, generation of pro-tumoral niches, promotion of angiogenesis and tumor cell proliferation.²³ For instance, recently Wang *et al.* demonstrated that healthy adipocytes incorporated hepatocarcinoma-derived exosomes. Then, those adipocytes changed their transcriptome and cytokine secretion patterns, and released exosomes creating a favorable microenvironment for tumor progression, enhancing angiogenesis and recruiting more macrophages.²⁴

Nowadays, other synthetic delivery systems are employed, such as liposomes and polymeric nanoparticles, which are the most widely used^{25,26} However, both systems have enormous challenges: to evade the immune system, to increase the blood circulation time and to elevate their stability without causing secondary cytotoxic effects.²⁷ Thus, exosomes are emerging as ideal candidates to deliver therapeutic drugs, proteins, nucleic acids or nanoparticles, providing several advantages compared with the liposomes or the polymer-based strategies. Firstly, they are naturally present in body fluids; therefore, they are stable in physiological conditions such as pH or temperature. Furthermore, they are less toxic and immunogenic compared to those synthetic vectors. Finally, they can deliver cargo to specific recipient cells due to their membrane proteins and lipids that are able to provide them with a fingerprint for the recognition and binding to specific receptors in the target cells. In



Pilar Martín Duque: Araid Researcher at IACS. Member of the DGA's NFP group and associated member at INA. BSc in Pharmacy, MSc in biotechnology and PhD in Medicine by UAM, Madrid. She enjoyed of post-doctoral or sabbaticals stays at MDAnderson-CC (Houston,USA), CancerResearch-UK, INSERM, Wake Forest University (North Carolina,USA), Imperial College (London) or Cornell University

(NYC,USA). Her CV has a H-index = 20, and 14 works as last author/corresponding. She has published more than 60 articles in international journals of high impact in the fields of gene therapy, cancer and medicine (including a Nature Medicine and a Nature Catalysis). She also has multiple communications for conferences, 3 doctoral theses directed, two research awards, three patents and two contracts with companies.



particular, this characteristic is crucial to transport therapies to certain areas where polymeric or liposomes are unable to reach, such as the brain, *via* BBB. In fact only the 2% of the central nervous system drugs are capable of crossing the BBB with the conventional platforms, which determines their low efficacy and their limitations in the transference to clinical trials.²⁸ Although further evidences are needed, some authors establish that exosomes may cross the BBB mainly following active endocytosis mechanisms.^{29,30} Furthermore, peripheral EVs can interact with the BBB leading to changes in the barrier's properties. A recent study, reports that in zebrafish neurons can remotely regulate blood–brain barrier integrity by delivering miR-132 through secretion of exosomes.³¹

For the development of exosome-based vehicles, the stability and the abundance of exosomes in body fluids would be very important points to consider.³² In two different studies, Sokolova *et al.* and Kalra *et al.*, observed whether extracellular vesicles were stable at least for 3 months at 37 °C, 4 °C, –20 °C and –80 °C.^{33,34} Nevertheless, extracellular vesicles stored at –80 °C were highly stable compared with the other storage temperatures tested.³³ To enable the development of novel exosome-based diagnostic and therapeutic tools, it is necessary to understand how modifications on the morphology and functionality of those vesicles might be made. Biological techniques (such as western blot, flow cytometry, polymerase chain reaction (PCR) or fluorescence microscopy) and physicochemical techniques (including dynamic light scattering (DLS), nanoparticle tracking analysis (NTA) or electronic microscopy) have to be employed to evaluate exosome content (proteins, lipids and nucleic acids) and also exosome morphology before and after customization.³⁵ This characterization provides useful information on how exosome modification could affect to their trafficking internalization or targeting abilities *in vivo* (key factors involved in the efficacy of the encapsulated therapy within them).

In summary, exosomes are highly stable nanovesicles involved in a wide range of normal and pathological processes and can be isolated from almost every cell and are stable and able to remain for a long time in the majority of body fluids.³² Furthermore, it is known that exosomes secrete specific molecules to receptor cells and that they can reach different target tissues according to the characteristics of the cells from which they are originated, endowing them with exciting possibilities regarding selective targeting.³⁶

However, there are major challenges to solve for the employment of exosomes as drug delivery agents in clinic. Firstly, a great difficulty for their translation to the clinic would be the low yield obtained with almost all the isolation methods, and also the presence of some impurities such as serum proteins or other extracellular vesicles.^{37,38} Secondly, when designing an exosome-based strategy, it is necessary to understand the implication of the exosomes in biological and pathological conditions in order to predict both short and long term safety issues and to increase the therapeutic effect of the exosomes cargo. Therefore, *in vivo* trafficking and behavior of exosomes as well as their interactions with the different organs need to be investigated more thoroughly before the translation

of exosome-based strategies therapies which are currently performed all over the world.¹⁹ Nonetheless, 84 clinical trials involving exosomes for both therapy and diagnosis are currently performed around the globe.³⁹

Overall, the important characteristics that makes exosomes suitable and feasible engineered vectors for the transport of theranostic tools are: (i) their content is protected by the lipid membrane. (ii) Their cargo and their membrane features are characteristic from the parental cell. (iii) They play an essential role in intercellular communication. (iv) They are highly stable in body fluids and (v) they can be stored for extended periods. For the reasons mentioned above, exosomes are ideal biological nanovectors for target therapeutic advanced therapies to specific pathological areas of the organism both for therapy and for diagnostic. In this review the recent combinations of genetic materials, viruses and nanotechnological tools together with exosomes are evaluated.

Exosomes to carry biological agents

Exosomes and transfer of proteins or nucleic acids

Introduction of therapeutic biomolecules within exosomes was not an easy task and several attempts were made. Haney *et al.* employed a passive incubating approach (incubation at room temperature without stirring or external forces) and a variety of active loading strategies (saponin, freeze–thaw cycles, sonication and extrusion) for the encapsulation of catalase (large protein of 240 kDa with antioxidant properties) in macrophage-derived exosomes. The encapsulation preserved its enzymatic activity, prolonged blood circulation time, and reduced immunogenicity, improving therapeutic efficacy.⁴⁰ They observed that when using active approaches, they obtained higher efficiencies. When applying sonication pulses, the ultrasounds compromises the integrity of the exosomal membrane allowing the enzyme to diffuse into the exosomes without disturbing exosomal membrane proteins or lipids. In the case of freeze–thaw cycles, exosomes are rapidly frozen and then they are thawed at room temperature and even sometimes, it is heated upon 37 °C. Regarding to extrusion strategies, exosomes and enzymes are put in contact and the mixture is extruded in a 10–400 nm filter under controlled conditions. Finally, incubating exosomes with membrane permeabilizers allows the formation of transitory pores increasing membrane permeabilization.⁴¹

Rather than proteins, nucleotides molecules are widely encapsulated in exosomes for the treatment of tumor or neurological diseases.⁴² For instance, Alvarez-Erviti *et al.* used electroporation to create small pores in exosome membranes in order to introduce siRNAs in dendritic cells derived exosomes for the treatment of Alzheimer disease. The loaded exosomes delivered a siRNA specifically to neurons, microglia, oligodendrocytes in the brain, knocking down BACE1 that is a therapeutic target in Alzheimer's disease.⁴³ In other study, parental cells were engineered to express the transmembrane domain of epidermal growth factor receptor (EGFR). Then, as cancerous cells overexpress the epidermal growth factor (EGF), those exosomes were used therapeutically to target *in vivo* an specific antitumoral miRNA in tumor tissues.⁴⁴ Recently, Han *et al.*



improved the therapeutic effect of miR-675, which is down-regulated in senescent cells, aging muscles and ischemic legs, by incorporating it into exosomes that were retained in a silk fibroin hydrogel. They observed a significantly improvement of the therapeutic effect of this mi-675 as antiaging factor and also preventing ischemic vascular dysfunction when it was encapsulating in exosomes.⁴⁵

Exosomes to transfer viral material

Viruses are currently a leader way to direct gene therapy strategies to the target areas, especially *in vivo*. However, some limitations such as their high immunogenicity and some organ-specific barriers have led to the search for new virus-based vectors.⁴⁶ Some strategies have tried to help by using liposomes or polymer-based vectors to offer a large hydrophilic lumen for the packaging of the virus.⁴⁷ Although it was an interesting option, its high cytotoxicity and its difficulty on a large-scale production, have made of it an option to dismiss.

For those reasons, the unique properties of EVs have encouraged to think about the novelty and advantages of the combination of viral vector systems together with exosomes, to solve the viral gene transfer issues.^{48–50} Interestingly, viruses can enter in the exosomes biogenesis pathway and incorporate its viral RNA genome, proteins, mRNAs and miRNAs.⁵¹ After the encapsulation, those exosomes would be able to transport the biologically active viral components from infected cells to the distant uninfected cells^{52–56} as it has been described how exosomes serve as protectors for virus miRNAs degradation.⁵⁷

Regarding the type of virus to be transferred in exosomes, there is a subset of previous studies describing interactions of EVs with viruses such as picornavirus, retrovirus, flavivirus, parvovirus, or reovirus.⁵⁸ It was demonstrated that dendritic cells infected with the human immunodeficiency virus (HIV) could secrete the virus out of the cells in association with exosomes.^{59–61} Also, *in vitro* exosomal transference of Epstein-Barr virus (EBV), human T-lymphotropic virus type 1 (HTLV-1), herpes simplex virus 1 (HSV-1) or Rift Valley fever virus (RVFV) mRNAs from the infected cells to the receptor cells was reported.^{62–66} But not only the mRNAs content was found in exosomes or EVs, as some authors have found the full-length viral RNA in some infections such as porcine reproductive and respiratory syndrome virus (PRRSV), foot-and-mouth disease virus (FMDV) and hepatitis A virus, as shown in Table 1.^{67,68}

Those studies were the base for the use of EVs for transfer of viruses commonly used for gene therapy. Several groups documented a subpopulation of EV particles that could be employed as a carrier system to deliver oncolytic adenoviruses to human tumors.^{69,70} Moreover, several studies have tested the ability of a subpopulation of adenoassociated virus (AAV) vectors interacting with exosomes to deliver genes.⁷¹ Those exosomes loaded with adenoassociated virus (exo-AAV), contained AAV vectors encoding the gene of interest as well as vector encoded proteins. Those novel virus-exosome vectors open new approaches for gene therapy applications.

Therefore, new therapeutic approaches based on viral gene therapy mediated by exosomes were widely described, in particular, those studies focused on exosome production in virus-infected cells to exploit their increasing targeting efficacy. Koppers *et al.* were the first ones suggesting that viral factors incorporated into the appropriate delivery vesicles could increase virus-encoded RNA delivery and proposed to engineer exosomes to carry tissue specific virus-derived molecules.⁷² In another study, Maguire *et al.* employed stomatitis virus glycoprotein (VSVG) to enhance transgene delivery, pseudotyping extracellular vesicles with adeno-associated virus.⁷³ Another virus glycoprotein, but from Rabies (RVG), was used for mirR-124 targeted delivery to the brain. In that work, the fusion of exosome protein LAMP2b, together with RVG, was used to modify exosomes, observing the knockdown expression of the target gene in a great area of the brain.⁷⁴ Finally, VSVG9 was used to improve the ability of exosomes to transfer therapeutic proteins, showing decreased gene expression in U87 and 293T tumoral cells.⁷⁵

Of all the viruses used on those approaches AAVs have taken most of the interest as they have been the preferential viruses used for gene therapy at preclinical or clinical trials, with many studies performed during decades that remarked their safety and efficacy. Indeed, its resistance neutralizing antibodies and the level of transgene expression was tested, and the primary results indicate that AAV vectors binding to exosomes increase transgene transfer levels as well as antibody resistance.⁷² The positive outcome obtained in those studies has led to subsequent studies to improve gene delivery of exo-AAV compared with non-enveloped AAV vectors in different tissues (brain, liver, heart, ear, and retina), which will be described in this review.

Most of the studies were performed applying systemic injection for the *in vivo* experiments, and they were able to transport transgenes to the distant uninfected organs and areas of disease. In the case of the brain, an *in vivo* model crossing the BBB using exo-AAV vectors was carried out. The *in vivo* intravenous delivery of exo-AAV vectors has been used to obtain successfully targeted transduction of interferon-beta cytokine in tumor stromal cells (astrocytes and tumor associated macrophages), contributing to the reduction of the tumor on mice.⁷⁶ Along the same lines, other studies show a GFP detection-enhancement of exo-AAV8 and exo-AAV9 *vs.* their non-encapsulated controls in the brain after intravenous injection at low doses,⁷⁷ representing a favourable approach for the genetic modification of the tumor microenvironment. Another organ in which exo-AAVs are actively used is the liver. *In vivo* efficiency of liver targeting of exo-AAV8 or exo-AAV5 vectors expressing human coagulation factor IX (hFIX) was checked on a mouse model of haemophilia B. An astonishing increase in hFIX transgene expression and hepatocyte distribution has been observed, especially at low vector doses, contributing to an exceptional correction of clotting time.⁷⁸ When it comes to the heart, Liang *et al.* has detected a significant improved cardiac function *in vivo* when comparing AAV-containing exosomes *vs.* mice treated with regular AAV gene therapy, opening a window for cardiovascular diseases.⁷⁹



Table 1 Studies relating exosomes with viral genetic material

Exosome origin (infected parental cell)	Virus	Viral genetic material	Function of viral material transfer	Reference
Hepatoma cells	HAV	Genomic RNA, viral particles	Viral spread	Longatti <i>et al.</i> , 2015 (ref. 52)
Hepatoma cells	HBV	mRNA	Viral spread	Kapoor <i>et al.</i> , 2017 (ref. 53); Yang <i>et al.</i> , 2017 (ref. 54)
Hepatoma cells	HCV	Full-length genomic RNA	Viral spread	Ramakrishnaiah <i>et al.</i> , 2013 (ref. 55); Dreux <i>et al.</i> , 2012 (ref. 56)
Dendritic cells/lymphocytes	HIV-1	Viral particles	Immune escape and viral spread	Wiley <i>et al.</i> , 2006 (ref. 59); Arenaccio <i>et al.</i> , 2015 (ref. 60); Sampey <i>et al.</i> , 2016 (ref. 61)
Liver cancer cells	HSV-1	Viral mRNA and microRNAs	Viral spread	Kalamvoki <i>et al.</i> , 2014 (ref. 62)
T cells	HTLV-1	mRNA and microRNAs	Viral spread	Jaworski <i>et al.</i> , 2014 (ref. 63)
Nasopharyngeal carcinoma cells/lymphoblastoid B lymphocytes	EBV	mRNA and microRNAs	Immune escape and viral spread	Canitano <i>et al.</i> , 2013 (ref. 64); Ahmed <i>et al.</i> , 2014 (ref. 65); Pegtel <i>et al.</i> , 2010 (ref. 57)
Kidney epithelial cells	RVFV	mRNA	Viral spread	Ashan <i>et al.</i> , 2016 (ref. 66)
Kidney cells	FMDV	Genomic RNA	Immune evasion	Zhang <i>et al.</i> , 2019 (ref. 67)
Kidney cells	PRRSV	Genomic RNA	Viral spread an immune evasion	Wang <i>et al.</i> , 2018 (ref. 68)

However, other studies administered the exo-viral vector by local administration. Indeed cochlear vestibular hair cells have been transduced with exo-AAV1 and exo-AAV9 vectors both *in vitro* and *in vivo*,⁸⁰ and a strengthened transduction of inner and outer cells in cochlear hair cells in culture has been found. Exo-AAV-LHFPL5 mediated expression has been studied in deaf mice, and surprisingly, after round window membrane (RWM) injection, a widespread expression of LHFPL5 throughout the cochlea and a restitution in sound and balance related abnormal movement are noticed. Thus, this study represents a novel strategy for rescue of inner-ear hearing. Apart from that, other studies have covered the intravitreal injection of exosomes in the retina of mice, and a powerful GFP expression has been detected around the optical disk, suggesting that intravitreal exosome-viral gene transfer could be a tool for basic research of the eye.⁸¹

Although the combination of exosomes with AAVs seems to be a promising strategy for high-efficient deliver gene therapy, the amount of the total exo-AAV vectors isolated from cell culture media is so low that still being a problem. In order to solve it, recent studies were focused on the design of approaches to increase exo-AAVs secretion, and they managed it by overexpressing CD9 in the parental cells.⁸² Exo-AAV-CD9 are more efficient in transduction of cells than standard exo-AAV, providing not only an excellent approach for the generation of exo-AAVs but also for stabilizing their interactions with AAVs. Moreover, the employment of AAV vectors has also other limitations including transgene's size limit or safety concerns.

However, although most of works focused on exosome production in virus-infected cells for targeting, the study of other applications of those virus-exosome complexes is an exciting new area of research. Applications as vaccines both for infective diseases⁸³ or for cancer vaccines⁸⁴ were studied. Currently, considering the evidences that antigens from some viruses from coronavirus family were found on plasma exosomes⁸⁵ and taking into account the good results obtained with other coronavirus-exosomal vaccines⁸⁶ there was a great interest in the development of vaccines for the new pandemic caused by SARS-CoV-2 virus. The speed of the investigations increased on this area and several groups are focused on testing exosomes for the development of an exosome-based vaccine for respiratory diseases with the first approaches, now just with empty vectors, in clinical trials.

In summary, preliminary results are promising, but some authors have claimed that preclinical studies with larger animal models are still necessary.⁵⁷ Taking into account that several viruses mentioned above associate with extracellular vesicles and that many others export viral components such as mRNA, this field could be the subject of study of multiple gene therapy groups. In the future, the combination of viral vector systems together with exosomes could allow us to deliver a large amount of therapies into some more areas that are difficult to reach while supposing a resistant mechanism to inactivation through antibodies.

Exosomes and nanotechnology

Even though most of the exosome-based tools consist in the combination of them with RNAs, proteins, viruses or chemotherapeutics, other types of advanced therapies can be loaded into those vesicles (Fig. 1).⁸⁷

Nanotechnology is considered the study, control and application of matter at nanoscale level and it has a large variety of applications, being nanomedicine one of the more important.⁸⁸ This discipline applies the unique properties of the nanomaterials such as their reduced size and their high relation surface/volume ratio to develop novel tools for control, treatment and diagnosis of biological systems.^{89,90} In particular, nanotechnology provides artificial nanocarriers (such as PLGA NPs, liposomes, dendrimers, metallic and inorganic structures) to vehicle different types of therapies, including gene therapies, to pathological tissues.⁹¹ Although there are no doubts on the goals achieved in this field, some drawbacks still exist. There is a lack of knowledge about the toxicity and the *in vivo* interactions of those nanomaterials. This fact limits their further clinical translation due to their potential systemic toxicity and immunogenicity and further research is needed.⁹²

Extracellular vesicles and in particular exosomes, provides nanotechnology with robust and feasible biological nanovehicles. In particular, thanks to their long circulation time, small size, low immunogenicity and targeting capability, exosomes exhibit ideal characteristics as vectors to deliver therapeutic nanotechnological cargo to specific cells. Therefore, considering the exosomal characteristics previously mentioned, those vesicles constitute an emerging type of nanocarriers




Fig. 1 Schematic representation of the combination of exosomes with conventional molecules (such as small molecules, biological agents as genetic material or proteins and common drugs) and advanced therapies, including products derived from nanotechnology.



formed by a functional lipid membrane and a hydrophilic core. They provide a stable environment to transport theranostic nanomaterials avoiding the immune response and allowing them to fuse with the plasma membrane to enter directly in the target cells. Thus, in the last five years, several studies have been focused on the combination of nanotechnology with exosomes.⁹³ Table 2 summarizes all the studies combining exosomes with nanotechnology. Fig. 2 shows a schematic representation of the different strategies widely employed for the loading of exosomes. Principally, two different approaches are being used to incorporate therapeutic agents into them (active or passive loading), resulting in different loading yields. The passive loading approach is the simplest way to incorporate nanoparticles and molecules within exosomes, and it consists in the incubation of the drug with the exosomes allowing them to enter following a concentration gradient. Although this method has very low loading efficiency (often less than 10%), a decade ago small lipophilic molecules were passively introduced in exosomes by incubating them at room temperature.⁹⁴ Therefore, more complex molecules including anti-oxidants and anti-inflammatory compounds were loaded inside exosomes, even nanoparticles. For instance, Altanerova *et al.*, showed that when labeling MSCs with carbohydrate-coated iron oxide nanoparticles, their released exosomes were loaded with those NPs. The magnetic nanoparticles packaged in MSCs-exosomes were successfully internalized by malignant cells and they served as magnetic hyperthermia antitumoral therapies killing cancerous cells in a dose-dependent manner.⁹⁵

Adipose stem cell, primary neuronal cells or macrophages have been also incubated with iron nanoparticles (USPIOs or SPIONS) and then EVs loaded within them were purified in order to generate microvesicles for MRI imaging and photodynamic therapy *in vivo*.^{96–98} Although some authors suggest that the indirect labeling of source cells is not recommended for exosome loading,^{99–101} it is one of the most widely employed techniques to achieve the encapsulation of NPs within exosomes (together with electroporation strategies).

Active transport is also an alternative for the generation of nanoparticle–exosome hybrids. Hood *et al.* loaded 5 nm SPIONS nanoparticles by active transport and electroporation approaches for exosome loading. They observed that the application of a simple electroporation pulse in the presence of a sugar (trehalose) minimized B16-F10 derived exosomes aggregation and improved the loading of 5 nm diameter SPIONS within exosomes by electroporation.¹⁰² The same method was employed by Hu *et al.* observing the accumulation of the exosomes in lymph nodes *in vivo* and their suitable properties as MRI diagnostic tools.¹⁰³

Moreover, the transfer of genetic material in exosome–nanoparticle vectors is still a possibility. Jia *et al.* created a multifunctional vector based on exosomes in which they encapsulated SPIONS, curcumin and neuropilin-1-targeted peptide for targeting and imaging specifically glioma cells *in vivo*. Firstly, they electroporated exosomes in the presence of SPIONS and curcumin and then they added the peptide by click chemistry following an EDC/NHS based method. The group successfully demonstrated the targeting capabilities of the

modified exosomes toward glioma cells and their therapeutic effect *in vivo*.¹⁰⁴

This year, Sancho-Albero *et al.*, developed a breakthrough strategy to synthesize *in situ* the NPs directly inside the exosomes rather than encapsulating them. They incubated a Pd ionic precursor with the exosomes, introduced in the exosomes by passive diffusion toward their membrane. Afterwards, the Pd nanosheets were created successfully inside exosomes by the conversion of P²⁺ to P⁰ using CO as gaseous reducing agent. The mildness of the procedure yielded to catalytically active Pd nanoparticles loaded into exosomes. This new hybrid system mediated Pd-triggered dealkylation reactions inside cells and displays a preferential tropism and selectivity for their parental cells.¹⁰¹

Finally, instead of encapsulating nanoparticles into exosomes some studies reported the attachment of them by binding the NPs to the exosomal surface or by engineering the membrane of the vesicles to create new exosome-based nano-platforms. As an example, Qi *et al.*, created a dual-functional exosomes-based cluster by anchoring transferrin-conjugated SPIONS on exosome surface through interactions with the Tf-Tf receptor for cancer therapy.¹⁰⁵ Rather than encapsulating AuNPs within exosomes and attaching them to their surface, some studies focused on the engineering of the exosomal membrane to decorate nanomaterials providing them with exosomal properties (stability and targeting). Khongkow *et al.* modified the AuNPs surface with brain-targeted exosomes following a serial extrusion approach. Thus, they equipped AuNPs with the functional lipidic membrane of exosomes demonstrating that the exosome modified AuNPs were internalized *in vivo* by brain cells thanks to the adhesion to the cell surface mediated by exosomes features.¹⁰⁶

Concerning to the applications, mainly all the reported works focused on the combination of SPIONS with exosomes for diagnostic applications based on MRI or for therapy mediated by magnetic hyperthermia strategies, but they could have many other uses such as gene transfer added to them. Only few works reported the combination of exosomes with gold nanoparticles (capable to absorb in the NIR region) by different physicochemical methods including passive loading, electroporation, thermal shock, sonication, saponin-assisted loading and labelling parental cells. They reached relatively low encapsulations efficacies when using the physicochemical methods (probably attributed to the membrane damage) compared with the labeling of their parental cells.¹⁰⁷ Specifically, encapsulations yields of 13.7%, 16.4%, 18.20%, 9.1%, 19.34% and 49.11% were obtained with passive and saponin assisted loading, two different thermal shock strategies, sonication and parental cell labeling, respectively. In other work, these authors encapsulate the same NPs within stem cells exosomes by incubating them with parental cells. They demonstrated that those exosomes maintain the tropism toward their source of cells, serving as specific and selective optical hyperthermia therapies.¹⁴ In the work reported by Betzer *et al.*, exosomes were labeled directly with glucose coated gold nanoparticles (from 5 to 20 nm of





Table 2 Studies combining exosomes with nanoparticles

Exosome origin (parental cell)	Type of advanced therapy	NPs size	Encapsulation strategy	Application	Reference
Mesenchymal stem cells	Venofor	65 nm	Labelling parental cells	<i>In vivo</i> magnetic hyperthermia therapy	Altanerova <i>et al.</i> , 2017 (ref. 95)
Adipose stem cells	USPIOs	5 to 7 nm	Labelling parental cells	<i>In vivo</i> magnetic resonance imaging	Busato <i>et al.</i> , 2016 (ref. 96)
Murine melanoma cells	SPIONs	5 nm	Passive loading and electroporation	Labelling	Hood <i>et al.</i> , 2014 (ref. 102)
Murine melanoma cell	SPIONs	5 nm	Electroporation	<i>In vivo</i> magnetic resonance imaging	Hu <i>et al.</i> , 2015 (ref. 103)
Glioma cells	SPIONs, curcumin and neupilon-1 targeted peptide	5 nm	Electroporation and click chemistry	<i>In vivo</i> targeted therapy and magnetic resonance imaging	Jia <i>et al.</i> , 2018 (ref. 104)
Murine melanoma cells	PEG-AuNPs	40–45 nm	Passive loading, electroporation, thermal shock, sonication, saponin-assisted loading and labelling parental cells	<i>In vitro</i> optical hyperthermia therapy and imaging by inherent reflection properties	Sancho-Albero <i>et al.</i> , 2019 (ref. 107)
Placental stem cells	PEG-AuNPs	40–45 nm	Labelling parental cells	Targeted <i>in vitro</i> optical hyperthermia therapy	Sancho-Albero <i>et al.</i> , 2019 (ref. 14)
Mesenchymal stem cells	Glucose-coated AuNPs	From 5 nm to 20 nm	Active loading (internalized and/or attached to the external surface)	<i>In vivo</i> CT imaging	Betzer <i>et al.</i> , 2017 (ref. 108)
PC-3 prostate cancer exosomes	AuNPs	13 nm	Labelling parental cells	Nucleic acid delivery system (gene downregulating)	Alhasan <i>et al.</i> , 2014 (ref. 109)
Breast adenocarcinoma cells	AuNPs with thiolated oligonucleotides	From 14 nm to 30 nm	Labelling parental cells	Nucleic acid delivery system (gene silencing)	Roma-Rodrigues <i>et al.</i> , 2017 (ref. 110)
HeLa cells	MOFs	250 nm	Fusion method	Smart and efficiency drug delivery	Illes <i>et al.</i> , 2017 (ref. 112)
Lung cancer cells	Pd nanosheets	2 nm	<i>In situ</i> generation inside exosomes	Targeted biorthogonal catalysis against cancer therapy	Sancho-Albero <i>et al.</i> , 2019 (ref. 101)
Blood exosomes	Transferrin-SPIONs	10 nm	Passive incubation	Cancer therapy	Qi <i>et al.</i> , 2016 (ref. 105)
Genetically engineered mammalian cells (RVG peptide)	AuNPs	48 nm	Extrusion	Enhancement of BBB penetration	Khongkorn <i>et al.</i> , 2018 (ref. 106)
Murine melanoma cells	Folic acid covered AuNPs-PEG	12 nm	Labelling parental cells	Penetration of exosomes specifically in metastatic small tumors	Lara <i>et al.</i> , 2020 (ref. 111)




Fig. 2 Strategies employed for exosome loading. (A) Exogenous methods (including passive and active methods) and (B) indirect approaches by labeling parental cells and taking advantage of the exosome biogenesis pathway.

diameter). AuNPs were incorporated on the exosomes assisted by a glucose-dependent active pathway. This new hybrid vector was then used for brain CT imaging *in vivo*.¹⁰⁸ Alhasan *et al.*, labelled parental cells (PC-3 prostate cancer cells) also with AuNPs conjugated to anti-miR21. Then, they isolated the exosomes from the supernatant and they transfected target cells, observing a selectively downregulation of miR21 (a miRNA related with the proliferation and progression of cancerous cells, which is significantly overexpressed in tumor tissue).¹⁰⁹ Similarly, Roma-Rodrigues *et al.*, also employed gold nanoparticles covered with oligonucleotides for selective silencing of RAB27A gene (crucial gene for the biogenesis and processing of exosomes) with a consequent decrease of exosomes production.¹¹⁰ This year, Lara *et al.*, created a novel protocol for the incorporation of folic acid covered gold nanoparticles into exosomes derived from B16-F10 cells by incubating them with the parental cells. They observed a preferential tropism toward small metastatic tumors compared with other organs *in vivo*.¹¹¹

Finally, not only iron and gold nanomaterials were incorporated into exosomes. Two years ago, Illes *et al.*, combined the properties of metal-organic frameworks nanoparticles (MOFsNPs) for their structural, chemical diversity, high loading efficiency and intrinsic biodegradability, together with exosomes. In particular, they created a smart exosome-coated MOF with “onboard-trigger” combining the release mechanism of exosomes with the biodegradation of the nanocarrier.¹¹²

Nanoparticles have risen a great interest in several areas of the biomedical field. Many different approaches could be applied either for therapy (hyperthermia, gene therapy, drug

delivery *etc.*) or for diagnostic (microfluidics, imaging *etc.*) offering a wide spectrum of options for the area of biomedicine. However, all these techniques have the same problems in common. Liver retention, lack of tropism to target areas and elimination during its circulation in the blood are factors that have prevented its transfer to the clinic. A large part of those problems could be solved by encapsulating those nanoparticles in vectors that bypassed those issues, such as exosomes.

Considering the attractiveness of combining the therapeutic and diagnostic applications that provide the nanotechnological tools and the ideal properties of exosomes as vehicles, it is not difficult to believe that in the following years exosome-based approaches could be translate into clinical settings. In fact, 84 clinical trials involving the use of exosomes were recorded (either active or completed). However, some drawbacks and limitations (such as more efficient purification strategies or the understanding of the interaction of exosomes with the living systems) have to be solved in order to successfully translate the findings obtained with animal models to the clinic.

Discussion

The use of exosomes as an ideal delivery system is attracting considerable attention on the last decade. Those natural carriers offer several advantages in terms of biocompatibility and specificity, an intrinsic long-term circulatory capability, low toxicity and ease of avoiding the immune system recognition and reducing clearance rates.⁸¹



Furthermore, exosomes present a long-term accumulation in organs or tissues and specific tropism for some cell types.⁸² They exhibit an extraordinary ability to interact with and accumulate in target cells and are able to overcome various biological barriers such as the cytoplasmic membrane and the BB unlike other delivery systems, which makes them ideal as therapeutic delivery molecules.⁸³

Taking all of this into account, exosomes are considered competitive targeted delivery vehicles for cellular or gene therapies with several advantages and a promising therapeutic value in the treatment of several disorders.^{113,114} However, the major drawbacks are the inefficiency on the extraction and isolation process, low encapsulation and loading efficiencies, low extraction yield, and potential delivery of unwanted cargo materials naturally present in the exosomes.⁸⁴ Therefore, further research in this field is needed in order to standardize optimal methods for exosome isolation, purification and storage, avoiding lack of reproducibility. In fact, several methods for exosome extraction are labor intensive, complex and give low yield, issue that have been recently improved with the use of promising techniques such as magnetic adhesion and flow cytometry in addition to loading techniques such as sonication, electroporation and incubation. Nevertheless, off-loading the content of exosome without distorting the structural integrity is very important in ensuring high loading and encapsulation efficiencies. This fact is particularly important in the case of using nanoparticles, because of their intrinsic size (2–50 nm) is too large to be encapsulated within exosomes. To solve this concern while achieving high encapsulations yields, some authors proposed the employment of passive methods in order to internalize an ionic precursor of the NPs followed by the *in situ* synthesis of the nanostructures directly inside the vesicles.¹⁰¹ Still early times for clinical trials but as the research in this field is growing very quickly, new information on preclinical studies would help to enhance the knowledge to be transfer to the clinic and to the market fairly soon.

Conflicts of interest

Authors declare no conflicts of interest.

Acknowledgements

Authors would like to thank, Dr Jesús Santamaría and Dr Manuel Arruebo for their support and Jorge Alejo for his help in this review. We thank the Instituto de Salud Carlos III (PI19/01007 and COV20/00155) and ERC Advanced Grant (ERC-2016-ADG-742684-CADENCE) for the financial support. CIBERBBN an initiative funded by the VI National R&D&i Plan 2008–2011 financed by the Instituto de Salud Carlos III with the assistance of the European Regional Development Fund. It was partially funded by the Aragon Government (T57_17R p) cofunded by Feder 2014–2020 “Building Europe from Aragon”. MS also acknowledge the Spanish Government for the receipt of a FPU predoctoral grant.

Notes and references

- 1 M. J. A. Wood, *Nat. Rev. Drug Discovery*, 2013, **12**, 347–357.
- 2 J. Meldolesi, *Curr. Biol.*, 2018, **28**, R435–R444.
- 3 M. Colombo, G. Raposo and C. Théry, *Annu. Rev. Cell Dev. Biol.*, 2014, **30**, 255–289.
- 4 B. J. Crenshaw, L. Gu, B. Sims and Q. L. Matthews, *Open Virol. J.*, 2018, **12**, 134–148.
- 5 S. Keller, J. Ridinger, A. K. Rupp, J. W. Janssen and P. Altevogt, *J. Transl. Med.*, 2011, **9**, 2–9.
- 6 T. Skotland, K. Sandvig and A. Llorente, *Prog. Lipid Res.*, 2017, **66**, 30–41.
- 7 A. De Gassart, C. Ge, B. Fe and M. Vidal, *Blood*, 2015, **102**, 4336–4345.
- 8 G. Raposo and W. Stoorvogel, *J. Cell Biol.*, 2013, **200**, 373–383.
- 9 Y. Zhang, Y. Liu, H. Liu and W. H. Tang, *Cell Biosci.*, 2019, **9**, 1–18.
- 10 X. Huang, T. Yuan, M. Tschannen, Z. Sun, H. Jaboc, M. Du, M. Liang, R. L. Dittmar, Y. Liu, M. Liand, M. Kohli, S. N. Thibodeau, L. Boardman and L. Wang, *BMC Genomics*, 2013, **14**, 1–14.
- 11 A. Waldenström and G. Ronquist, *Circ. Res.*, 2014, **114**, 315–324.
- 12 B. K. Thakur, H. Zhang, A. Becker, I. Matei, Y. Huan, B. Costa-Silva, Y. Zheng, A. Hoshino, H. Brazier, J. Xiang, C. Williams, R. Rodriguez-Barrueco, J. M. Silva, W. Zhang, S. Hearn, O. Elemento, N. Paknejad, K. Manova-Todorova, K. Welte, J. Bromberg, H. Peinado and D. Lyden, *Cell Res.*, 2014, **24**, 766–769.
- 13 C. Rajagopal and K. B. Harikumar, *Front. Oncol.*, 2018, **8**, 1–13.
- 14 M. Sancho-albero, N. Navascués, G. Mendoza, V. Sebastián, M. Arruebo, P. Martín-Duque and J. Santamaría, *J. Nanobiotechnol.*, 2019, **17**, 1–13.
- 15 E. Willms, H. J. Johansson, I. Mäger, K. E. M. Blomberg, M. Sadik, A. Alaarg, C. I. E. Smith, J. Lehtiö, S. E. L. Andaloussi, M. J. A. Wood and P. Vader, *Sci. Rep.*, 2016, **6**, 1–12.
- 16 J. Palma, S. C. Yaddanapudi, L. Pigati, M. A. Havens, S. Jeong, G. A. Winer, K. Mary, E. Weimer, B. Stern, M. L. Hastings, D. M. Duelli and S. Jeong, *Nucleic Acids Res.*, 2012, **40**, 9125–9138.
- 17 J. De Toro, L. Herschlik, C. Waldner and C. Mongini, *Front. Immunol.*, 2015, **6**, 1–12.
- 18 F. Shahabipour, N. Barati, T. P. Johnston, G. Derosa, P. Maffioli and A. Sahebkar, *J. Cell. Physiol.*, 2017, **232**, 1660–1668.
- 19 D. Ha, N. Yang and V. Nadithe, *Acta Pharm. Sin. B*, 2016, **6**, 287–296.
- 20 G. Lachenal, K. Pernet-Gallay, M. Chivet, F. J. Hemming, A. Belly, G. Bodon, B. Blot, G. Haase, Y. Goldberg and R. Sadoul, *Mol. Cell. Neurosci.*, 2011, **46**, 409–418.
- 21 T. Xiao, W. Zhang, B. Jiao, C.-Z. Pan, X. Liu and L. Shen, *Transl. Neurodegener.*, 2017, **6**, 1–6.



- 22 N. Amabile, P. E. Ratou, A. Tedgui and C. M. Boulanger, *Semin. Thromb. Hemostasis*, 2010, **36**, 907–916.
- 23 C. Kahlert and R. Kalluri, *J. Mol. Med.*, 2013, **91**, 431–437.
- 24 S. Wang, M. Xu, X. Li, X. Su, X. C. Zhao, A. Keating and R. C. Zhao, *J. Hematol. Oncol.*, 2018, **11**, 1–14.
- 25 L. Sercombe, T. Veerati, F. Moheimani, S. Y. Wu and S. Hua, *Front. Pharmacol.*, 2015, **6**, 1–13.
- 26 U. Agrawal, R. Sharma, M. Gupta and S. P. Vyas, Is nanotechnology a boon for oral drug delivery?, *Drug Discovery Today*, 2014, **19**, 1530–1546.
- 27 K. Raemdonck, K. Braeckmans, J. Demeester and S. C. De Smedt, *Chem. Soc. Rev.*, 2014, **43**, 444–472.
- 28 W. M. Pardridge, *J. Cereb. Blood Flow Metab.*, 2012, **32**, 1959–1972.
- 29 T. Druzhkova and A. A. Yakovlev, *Neurochem. J.*, 2018, **12**, 195–204.
- 30 C. Théry, A. I. Curie and U. Insem, *F1000 Biol. Rep.*, 2011, **8**, 1–8.
- 31 Z. Zhao and B. Zlokovic, *Cell Res.*, 2017, **27**, 849–850.
- 32 S. Boukouris and S. Mathivanan, *Proteomics: Clin. Appl.*, 2015, **9**, 358–367.
- 33 V. Sokolova, A. K. Ludwig, S. Jornung, O. Rotan, P. A. Horn, M. Epple and B. Giebel, *Colloids Surf., B*, 2011, **87**, 146–150.
- 34 H. Kalra, C. G. Adda, L. Liem, C. S. Ang, A. Mechler, R. J. Simpson, M. D. Hulett and S. Mathivanan, *Proteomics*, 2013, **13**, 3354–3364.
- 35 J. L. Hood, *Nanomedicine*, 2016, **11**, 1745–1756.
- 36 S. Rana, S. Yue, D. Stadel and M. Zöller, *Int. J. Biochem. Cell Biol.*, 2012, **44**, 1574–1584.
- 37 Y. Toda, K. Takata, Y. Nakagawa, H. Kawakami, S. Fujioka, K. Kobayashi, Y. Hattori, Y. Kitamura, K. Akaji and E. Ashihara, *Biochem. Biophys. Res. Commun.*, 2015, **456**, 768–773.
- 38 K. E. Petersen, E. Manangon, J. L. Hood, S. A. Wickline, D. P. Fernandez, W. P. Johnson and B. K. Gale, *Anal. Bioanal. Chem.*, 2014, **406**, 7855–7866.
- 39 Clinical Trials, Pieejams, https://clinicaltrials.gov/ct2/results?term=Exosome&cond=Cancer&Search=Clear&age_v=&gndr=&type=&rslt=.
- 40 M. J. Haney, N. L. Lyachko, Y. Zhao, R. Gupta, E. G. Plotnikova, Z. He, T. Patel, A. Piroyan, M. Sokolsky, A. V. Kabanov and E. V. Batrakova, *J. Controlled Release*, 2016, **21**, 4062–4072.
- 41 I. Podolak, A. Galanty and D. Sobolewska, *Phytochem. Rev.*, 2010, **9**, 425–474.
- 42 M. Lu, H. Xing, Z. Xun, T. Yang, P. Ding, C. Cai, D. Wang and X. Zhao, *Asian J. Pharm. Sci.*, 2018, **13**, 1–11.
- 43 L. Alvarez-Erviti, Y. Seow, H. Ying, C. Betts, S. Lakhali and M. J. A. Wood, *Nat. Biotechnol.*, 2011, **29**, 3–4.
- 44 S. I. Ohno, M. Takanashi, K. Sudo, S. Ueda, A. Ishikawa, N. Matsuyama, K. Fujita, T. Mizutani, T. Ohgi, T. Ochiya, N. Gotoh and M. Kuroda, *Mol. Ther.*, 2013, **21**, 185–191.
- 45 C. Han, J. Zhou, B. Liu, C. Liang, X. Pan, Y. Shang, Y. Chang, Y. Wang, L. Shao, B. Shu, J. Wang, Q. Yin, X.-Y. Yu and Y. Li, *Mater. Sci. Eng., C*, 2019, **99**, 322–332.
- 46 Y. Wang, *Front. Immunol.*, 2018, **9**, 1–8.
- 47 Y. Wang, H. Huang, H. Zou, X. Tian, J. Hu, P. Qiu, H. Hu and G. Yan, *Mol. Pharm.*, 2019, **16**, 779–785.
- 48 S. G. van der Grein, K. A. Y. Defourny, E. F. J. Slot and E. N. M. N. Hoen, *Semin. Immunopathol.*, 2018, **40**, 491–504.
- 49 Z. Yao, Y. Qiao, X. Li, J. Chen, J. Ding, L. Bai, F. Shen, B. Shi, J. Liu, L. Peng, J. Li and Z. Yuan, *J. Virol.*, 2018, **92**, 1–21.
- 50 E. Nolte, T. Cremer, R. C. Gallo and L. B. Margolis, *PNAS*, 2016, **113**, 9155–9161.
- 51 M. Drahanovsky, *Intech*, 2016, **1**, 13.
- 52 A. T. Longatti, *Viruses*, 2015, **7**, 6707–6715.
- 53 N. Kapoor and R. Chadha, *Virus Res.*, 2017, **14**, 166–174.
- 54 Y. Yang, Q. Han, Z. Hou, C. Zhang, Z. Tian and J. Zhang, *Cell. Mol. Immunol.*, 2016, **13**, 1–11.
- 55 V. Ramakrishnaiah, C. Thumann, I. Fofana, F. Habersetzer, Q. Pan, P. E. de Ruiter, R. Willemsen, J. A. Demmers, V. S. Waj, G. Jenster, J. Kwekkeboom, H. W. Tilanus, B. L. Haagmans, T. F. Baumert and L. J. van der Laan, *PNAS*, 2013, **110**, 13109–13113.
- 56 M. Dreux, U. Garaigorta, B. Boyd, E. Décembre, J. Chung, C. Whitten-bauer, S. Wieland and F. V. Chisari, *Cell Host Microbe*, 2013, **12**, 558–570.
- 57 D. M. Pegtel, K. Cosmopoulos, D. A. Thorley-lawson and M. A. J. Van Eijndhoven, *PNAS*, 2010, **107**, 1–6.
- 58 B. György and C. A. Maguire, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2017, **10**, 1–13.
- 59 R. D. Wiley and S. Gummuluru, *PNAS*, 2006, **2005**, 1–6.
- 60 C. Arenaccio, S. Anticoli, F. Manfredi, C. Chiozzini, E. Olivetta and M. Federico, *Retrovirology*, 2015, **12**, 1–17.
- 61 G. C. Sampey, M. Saifuddin, A. Schwab, R. Barclay, S. Punya, M.-C. Chung, X. R. M. Hakami, M. A. Zadeh, B. Lepene, Z. A. Klase, N. El-hage, M. Young, S. Iordanskiy and F. Kashanchi, *J. Biol. Chem.*, 2016, **291**, 1251–1266.
- 62 M. Kalamvoki, T. Du and B. Roizman, *PNAS*, 2014, **111**, 4991–4996.
- 63 E. Jaworski, A. Narayanan, R. Van Duyne, S. Shabbeer-Meyering, S. Iordanskiy, M. Saifuddin, R. Das, P. V. Alfonso, G. C. Sampey, M. Chung, A. Popratiloff, B. Shrestha, M. Shegal, P. Jain, A. Vertes, R. Mahieux and F. Kashanchi, *Biol. Chem.*, 2014, **289**, 22284–22305.
- 64 A. Canitano, G. Venturi, M. Borghi, M. Grazia and S. Fais, *Cancer Lett.*, 2013, **337**, 193–199.
- 65 W. Ahmed, P. S. Philip, S. A. Tariq and G. Khan, *PLoS One*, 2014, **9**, e99163.
- 66 N. A. Ahsan, G. C. Sampey, B. Lepene, Y. Akpamagbo, R. A. Barclay, S. Iordanskiy, R. M. Hakami and F. Kashanchi, *Front. Microbiol.*, 2016, **7**, 139.
- 67 K. Zhang, S. Xu, X. Shi, G. Xu, C. Shen, X. Liu and H. Zheng, *Vet. Microbiol.*, 2019, **233**, 164–173.
- 68 T. Wang, L. Fang, F. Zhao, D. Wang and S. Xiao, *J. Virol.*, 2018, **92**, e01734–17.
- 69 L. Ran, X. Tan, Y. Li, H. Shang, R. Ma, T. Ji, W. Dong, T. Tong, Y. Liu, D. Chen, X. Yin, X. Liang, K. Tang, J. Ma, T. Y. Zhang, X. Cao, Z. Hu, X. Win and B. Huang, *Biomaterials*, 2016, **89**, 56–66.
- 70 H. Saari, T. Turunen, A. Löhmus, M. Turunen, M. Jalasvuori, S. J. Butcher, S. Ylä-herttua, T. Viitala,



- V. Cerullo, R. Pia, M. Siljander and M. Yliperttula, *J. Extracell. Vesicles*, 2020, **9**, 1–24.
- 71 Z. Fitzpatrick, M. H. W. Crommentuijn, D. Mu and C. A. Maguire, *Biomaterials*, 2014, **35**, 7598–7609.
- 72 D. Koppers-lalic, M. M. Hogenboom, J. M. Middeldorp and D. M. Pegtel, *Adv. Drug Delivery Rev.*, 2013, **65**, 348–356.
- 73 C. A. Maguire, L. Balaj, S. Sivaraman, M. H. Crommentuijn, M. Ericsson, L. Mincheva-Nilsson, V. Baranoc, D. Gianni, B. A. Tannous, M. Sena-Esteves, X. O. Breakefield and J. Skog, *Mol. Ther.*, 2012, **20**, 960–971.
- 74 L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhali and M. J. A. Wood, *Nat. Biotechnol.*, 2011, **29**, 341–345.
- 75 C. Meyer, J. Losacco, Z. Stickney, L. Li, G. Marriott and B. Lu, *Int. J. Nanomed.*, 2017, **12**, 3153–3170.
- 76 A. Volak, S. G. LeRoy, J. S. Natasan, D. J. Park, P. S. Cheah, A. Maus, Z. Fitzpatrick, E. Hudry, K. Pinkham, S. Gandhi, B. T. Hyman, D. Mu, D. GuhaSarkar, A. O. Stemmer-Tachmimov, M. Sena-Esteves, C. E. Badr and C. A. Maguire, *J. Neuro-Oncol.*, 2018, **139**, 293–305.
- 77 E. Hudry, C. Martin, S. Gadhi, B. Gyögy, B. I. Sheffer, D. Mu, S. F. Merkel, F. Mingozzi, Z. Fitzpatrick, H. Dimant, M. Masek, T. Ragan, S. Tan, A. R. Brisson, S. H. Ramirez, B. T. Hyman and X. A. Maguire, *Gene Ther.*, 2016, **23**, 380–392.
- 78 A. Meliani, F. Boisgerault, Z. Fitzpatrick, S. Marmier, C. Leborgne, F. Collaud, M. S. Sola, S. Charles, G. Ronzitti, A. Vignaud, L. van Wittenbergeje, M. Marolleau, F. Jouen, S. Tan, O. Boyer, O. Christophe, A. R. Brisson, C. A. Maguire and F. Mingozzi, *Blood Adv.*, 2017, **1**, 2019–2031.
- 79 Y. Liang, P. Mathiyalagan, E. Kohlbrenner, E. Chepurko, D. Jeong, D. ceholski, N. Dubois, R. Hajjar and S. Sahoo, *Circulation*, 2017, **136**, A15439.
- 80 B. György, C. Sage, A. A. Indshykulian, D. O. Sscheffer, A. R. Brisson, S. Tan, C. Wu, A. Volak, D. Mu, P. I. Tamvakologos, Y. Li, Z. Fitzpatrick, M. Ericsson, X. O. Breakefield, D. P. Corey and C. A. Maguire, *Mol. Ther.*, 2017, **25**, 379–391.
- 81 S. J. Wassmer, L. S. Carvalho, B. György, L. H. Vandenberghe and C. A. Maguire, *Sci. Rep.*, 2017, **7**, 1–10.
- 82 L. T. Schiller, N. Lemus-Diaz, R. Rinaldi Ferreira, K. O. Böker and J. Gruber, *Mol. Ther.–Methods Clin. Dev.*, 2018, **9**, 278–287.
- 83 C. M. Bliss, A. J. Parsons, R. Nachbagauer, J. R. Hamilton, F. Cappuccini, M. Ulaszewska, J. P. Webber, A. Clayton, A. V. S. Hill and L. Coughlan, *Mol. Ther.–Methods Clin. Dev.*, 2020, **16**, 108–125.
- 84 Z. C. Hartman, J. Wei, O. K. Glass, H. Guo, G. Lei, X.-Y. Yang, T. Osada, A. Hobeika, A. Delcayre, J.-B. Le Pecq, M. A. Morse, T. M. Clay and H. K. Lyster, *Vaccine*, 2011, **29**, 9361–9367.
- 85 M. Gunasekaran, S. Bansal, R. Ravichandran, M. Sharma, S. Perincheri, F. Rodriguez, R. Hachem, C. E. Fisher, A. P. Limaye, A. Omar, M. A. Smith, R. M. Bremner and T. Mohanakumar, *J. Heart Lung Transplant.*, 2020, **39**, 379–388.
- 86 S. Kuate, J. Cinatl, H. W. Doerr and K. Uberla, *Virology*, 2007, **362**, 26–37.
- 87 K. B. Johnsen, J. M. Gudbergsson, M. N. Skov, K. Pilgaard, T. Moos and M. Doroux, *Biochim. Biophys. Acta, Rev. Cancer*, 2014, **1**, 75–87.
- 88 A. D. Maynard, *Ann. Occup. Hyg.*, 2007, **51**, 1–12.
- 89 S. M. Moghimi, A. Christy Hunter and J. Clifford Murray, *FASEB J.*, 2005, **19**, 311–330.
- 90 O. V. Salata, *J. Nanobiotechnology*, 2004, **6**, 1–6.
- 91 J. K. Patra, G. Das, L. F. Fraceto, E. V. R. Campos, M. P. Rodriguez-Torres, L. S. A.-T. R. Grillo, M. K. Swamy, S. Sharma, S. Habtemariam and H.-S. Shin, *J. Nanobiotechnology*, 2018, **16**, 1–33.
- 92 Y. Min, J. M. Caster, M. J. Eblan and A. Z. Wang, *Chem. Rev.*, 2015, **115**, 11147–11190.
- 93 B. Yang, Y. Chen and J. Shi, *Adv. Mater.*, 2019, **31**, 1–33.
- 94 A. Kalani, A. Tyagi and N. Tyagi, *Mol. Neurobiol.*, 2009, **19**, 389–399.
- 95 U. Altanerova, M. Babincova, P. Babinec, K. Benejova, J. Jakubecova, V. Altanerova, M. Zduriencikova, V. Rapiska and C. A. Taner, *Int. J. Nanomed.*, 2017, **12**, 7923–7936.
- 96 A. Busato, R. Bonafede, P. Bontempi, I. Scambi, L. Schiaffino, D. Benati, M. Malatesta, A. Sbarbati, P. Marzola and R. Mariotti, *Curr. Protoc. Cell Biol.*, 2017, **75**, 3–44.
- 97 J. Neubert and J. Glumm, *Neural Regener. Res.*, 2016, **11**, 61–63.
- 98 A. K. Silva, N. Luciani, F. Gazeau, K. Aubertin, S. Bonneau, C. Chauvierre, D. Letourneur and C. Wihelm, *Nanomedicine*, 2015, **11**, 645–655.
- 99 C. Liu and C. Su, *Theranostics*, 2019, **9**, 1015–1028.
- 100 X. Luan, K. Sansanaphongpricha, I. Myers, H. Chen, H. Yuan and D. Sun, *Acta Pharmacol. Sin.*, 2017, **38**, 754–763.
- 101 M. Sancho-Albero, B. Rubio-Ruiz, A. M. Pérez-López, V. Sebastián, P. Martín-Duque, M. Arruebo, J. Santamaría and A. Unciti-Broceta, *Nat. Catal.*, 2019, **2**, 864–872.
- 102 J. L. Hood, M. J. Scott and S. A. Wickline, *Anal. Biochem.*, 2014, **448**, 41–49.
- 103 L. Hu, S. A. Wickline and J. L. Hood, *Anal. Chem.*, 2015, **25**, 368–379.
- 104 G. Jia, Y. Han, Y. An, Y. Ding, C. H. X. Wang and W. Tang, *Biomaterials*, 2018, **178**, 302–316.
- 105 H. Qi, C. Liu, L. Long, Y. Ren, S. Zhang, X. Chang, X. Wian, H. Jia, J. Zhao, J. Sun, X. Hou, X. Yuang and C. Kang, *ACS Nano*, 2016, **10**, 3323–3333.
- 106 M. Khongkow, T. Yata and S. Boonrungsiman, *Sci. Rep.*, 2019, **9**, 1–9.
- 107 M. Sancho-Albero, M. M. Encabo-Berzosa, M. Beltrán-Visiedo, L. Fernández-Messina, V. Sebastián, F. Sánchez-Madrid, M. Arruebo, J. Santamaría and P. Martín-Duque, *Nanoscale*, 2019, **11**, 18825–18836.
- 108 O. Betzer, N. Perets, A. Angel, M. Motiei, T. Sadan, G. Yadid, D. Offen and R. Popoetz, *ACS Nano*, 2017, **11**, 10883–10893.



Review

- 109 A. H. Alhasan, P. C. Patel, C. H. J. Choi and C. A. Mirkin, *Small*, 2009, **6**, 247–253.
- 110 C. Roma-Rodrigues, F. Pereira, A. P. Aves de Matos, M. Fernandes, P. V. Baptista and A. R. Fernandes, *Nanomedicine*, 2017, **13**, 1389–1398.
- 111 P. Lara, S. P. Florez, E. S. Huenuleo, I. Polakovicova, S. Guerrero, L. L. Gonzalez, A. Campos, L. Muñoz, C. J. Cordero, M. V. Godoy, J. Cancino, E. Arias, J. Villegas, L. J. Cruz, F. Albericio, E. Araya, A. H. Corvalan, A. F. G. Quest and M. J. Kogan, *J. Nanobiotechnology*, 2020, **18**, 1–17.
- 112 B. Illes, P. Hirshle, S. Barnert, V. Cauda, S. Wuttke and H. Engelke, *Chem. Mater.*, 2017, **29**, 8042–8046.
- 113 W. J. Goh, S. Zou, W. Y. Ong, F. Torta, A. F. Alexandra, R. M. Schiffelers, G. Storm, J. W. Wang, B. Czarny and G. Pastorin, *Sci. Rep.*, 2017, **7**, 1–10.
- 114 P. Akuma, O. D. Okagu and C. C. Udenigwe, *Front. Sustain. Food Syst.*, 2019, **3**, 1–8.

